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Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessively inherited autoinflammatory disease which is
clinically manifested with periodic episodes of fever,
polyserositis and arthritis. Among the Turkish, Arabic,
Armenian and Jewish population the incidence rate
ranges between 1 in 500 to 1000. The severity of the
disease depends mostly on the MEFV gene mutation
variations.
Objective
The objective of this study is to reveal a single center
follow-up experience of a wide amount of childhood
FMF patients from different regions around Turkey in
terms of the demographic and clinical features, the
genetic diversity and treatment response.
Material-methods
708 children diagnosed with FMF and under treatment
of colchicine for at least 6 months that are seen out
patiently in our Pediatric Rheumatology Clinic between
November 2014 and March 2015 were reviewed retro-
spectively with the data based on the patient records
and also taken from the parents.
Results
708 patients consisting 362 males and 246 females that
are diagnosed with FMF were included in the study.
The mean age of the patients by the time of the study
was found to be 12,3 ± 4,4 years, while the mean age at
the onset of the disease was 4,8 ± 3,4 years and at diag-
nosis was 7,3 ± 3,8 years. The consanguinity rate was
resulted to be %29,2 and positive family history was
detected in 370 (52,3%) patients.
In 634 (89,5%) of patients, episodes of abdominal pain
for at least 6 hours due to peritonitis; in 629, (88.8%)
periods of fever for at least 12 hours and in 122 (17,2%),
chest pain probably due to pleuritis was found. 213
(30,1%) patients experienced erysipelas like erythema
and 288 (40,7%) were diagnosed with findings of arthri-
tis that last for at least a day. In 467 (66%) cases exer-
tional leg pain and in 29 (4,1%) myalgia are among the
complaints and enthesitis was reported in 26 (3,7%)
patients. Pericarditis was developed only in 2 (0,3%)
patients. The mean duration of the attack was found to
be 64,8 ± 38,5 hours. In 38 (53,4%) patients with appen-
dectomy was performed due to unresolved episodes of
abdominal pain.
The patients were investigated about the MEFV gene
mutations and M694V homozygote mutation was found
in 154 (21,8%) and M694V heterozygote in 141 (19,8%)
children. All the other mutations in exon 10 region
(M680I, V726A, M694I) in a compound heterozygous
manner with M694V mutation were detected to be in
90 (12,7%) cases and the rate of patients that is a carrier
of only one copy of exon 10 region mutations other
than M694V was %13. The rest of the mutations (in
exon 2,3,5 regions) were revealed in 45 (6,4%) children.
In 45 (6,4%) of patients none of the so far known main
mutations were shown.
Amyloidosis had been developed only in two cases
both of whom were suffering from the disease process
for at least 10 years and showing defective compliance
to the colchicine treatment. One of them was a 20 years
old M694V homozygote mutation carrier and the other
was happened to be compound heterozygous with
M694V/M680I mutations.
All of the patients were under colchicine treatment, of
which 57 (8,1%) were uncompliant. As the side effects of
the treatment were evaluated, diarrhea was found out to
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the elevation in serum transaminase levels by 10 (1.4%).
Only in one case leukopenia and also in another case alo-
pecia developed.
The response to colchicine treatment was investigated
and in 559 (79%) patients no episode occurred in the
last year. In 149 (21%) cases periodic episodes were
reported by the mean rate of 4,9 ± 4,4 per year (median
3/year, ranging between 1-24/year). After the follow up
under treatment for at least 6 months the mean episode
duration was decreased to 39,7 ± 29,4 hours (median
24 hours ranging between 6-168 hours).
The patients who are taking their colchicine treatment
properly but still complaining about at least 6 episodes
of any possible manifestations per year were considered
resistant and were found to be in the rate of 47 (6,6%)
in our cohort. In resistant cases, the most detected
mutations were homozygous M694V (71.4%) in the first
range and then compound heterozygosity with M694V/
M680I.
Conclusion
The diagnosis of childhood FMF is frequently encountered
in our country. The most severe clinical presentation
occurs as a result of M694V and other exon 10 region
mutations. With the absolute compliance to treatment;
the episodes disappear and amyloidosis, the most dreadful
complication of the disease, can be prevented.
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